Publications by authors named "D Pectasides"
Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Breast
February 2024
Article Synopsis
- Dose-dense sequential (dds) chemotherapy has positively impacted long-term survival rates in early breast cancer patients, as shown in the observational trial HE 10/10.
- The study analyzed the role of tumor infiltrating lymphocytes (TILs) and CD8 lymphocytes in predicting outcomes, finding that higher levels are linked to better survival.
- With a median follow-up of over 10 years, the study reported disease-free survival (DFS) at 78.4% and overall survival (OS) at 81.7%, highlighting the regimen's efficacy and safety.
Purpose: We conducted a phase II randomized noncomparative window of opportunity (WOO) trial to evaluate the inhibition of cellular proliferation and the modulation of immune microenvironment after treatment with olaparib alone or in combination with cisplatin or durvalumab in patients with operable head and neck squamous cell carcinoma (HNSCC).
Experimental Design: Forty-one patients with HNSCC were randomized to cisplatin plus olaparib (arm A), olaparib alone (arm B), no treatment (arm C) or durvalumab plus olaparib (arm D). The primary endpoint was to evaluate the percentage of patients in each arm that achieved a reduction of at least 25% in Ki67.
Background: Third-generation aromatase inhibitors (AIs) are the mainstay of treatment in hormone receptor (HR)-positive breast cancer. Even though it is considered to be a well-tolerated therapy, AI-induced musculoskeletal symptoms are common and may be accused for treatment discontinuation. Recently, selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors changed the therapeutic setting, and currently, ribociclib, palbociclib, and abemaciclib are all approved in combination with nonsteroidal AIs in patients with ER-positive, HER2-negative advanced or metastatic breast cancer.
View Article and Find Full Text PDFAssociation between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study.
Cancers (Basel)
November 2022
Article Synopsis
- A study investigated the role of CD8+ tumor-infiltrating lymphocytes (TILs) in early breast cancer patients who received adjuvant chemotherapy, revealing important prognostic implications based on their density in tumors.
- Out of 928 patients, 627 had CD8+ data, with about 25% showing high levels of CD8 TILs, which were linked to more aggressive tumor characteristics and better survival rates.
- High intratumoral (iCD8) and total (tCD8) counts were associated with longer disease-free survival (DFS) and overall survival (OS), indicating their potential as beneficial prognostic factors in managing early breast cancer.
Background: Bladder cancer (BC) is a heterogeneous malignancy with dismal outcome.
Patients And Methods: Mutations in genes, altered or linked to platinum sensitivity in BC, were examined in 66 patients' tumors along with tumor infiltrating lymphocytes (TILs) density and MMR, PD-L1 and CD8 protein expression, as well as basal and luminal subtypes, defined by protein expression of markers, including CK5/6 and GATA3 or CK20, respectively.
Results: 41 tumors harbored mutations, mainly in TP53 (38%), ARID1A (17%) and the DNA damage response and repair (DDR) genes ERCC2 (17%) and BRCA2 (15%).